You are here

Vistin Pharma ASA : Invitation to presentation of Q4 2017 results



Oslo, 22 February 2018

Vistin Pharma ASA (OSE: VISTIN) will release its fourth quarter 2017 results on Tuesday 27 February 2018.

The results will be presented by Vistin Pharma's CEO Kjell-Erik Nordby and CFO Gunnar Manum at 08:30 CET at Carnegie AS, Fjordalleen 16, Oslo, Norway. The presentation will be held in Norwegian.
  
The quarterly report and the presentation material will be available on www.vistin.com/investors and www.newsweb.no, as well as on news wires.

Vistin Pharma welcomes all interested parties.

For further information, please contact:

Gunnar Manum
CFO
+47 95 17 91 90
gunnar.manum@vistin.com


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Thursday, February 22, 2018 - 09:38

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations